Tau PET Imaging in Opioid Use Disorder

NCT05651516 | Active Not Recruiting Early Phase 1 FDA Drug

• 1 other identifier: 852095
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators plan to enroll up to 60 adult subjects in this study. There will be three groups of up to 20 subjects each in this study. Group 1: individuals with OUD and a history of at least one opioid-related OD in the past 5 years that required naloxone treatment reversal: OUD/OD+ Group 2: individuals with OUD without a lifetime history of opioid-related OD OUD/OD- Group 3: Healthy controls without a lifetime OUD: HCs PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.

Conditions

Opioid-Related Disorders

Keywords

Tau; PET/CT

Outcome Measures

Primary Outcomes (1)

• Standardized uptake value ratio (SUVr),

  • \[18F\]PI-2620PET SUVr regional uptake (occipital cortex, medial parietal/posterior cingulate cortex, temporoparietal cortex, medial temporal lobe, frontal lobes).

  8 weeks

Secondary Outcomes (2)

• MRI cortical volume

  8 weeks

• MRI cortical thickness

  8 weeks

Other Outcomes (1)

• Neurocognitive test results

  8 weeks

Study Arms (1)

Tau PET/CT

EXPERIMENTAL

PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed. Participants will undergo approximately 30 minutes of static PET scanning of the brain and body starting approximately 45 minutes post injection of \[18F\]PI-2620. All images will be corrected for scatter and measured photon attenuation and reconstructed using standard reconstruction techniques. Standardized uptake value ratio (SUVr), the ratio of regional to reference uptake, will be calculated with cerebellum as reference, where NFTs are generally not present in neurodegenerative disorders, hence likely not in OUD. Subjects in all three groups undergo a brain MRI including a structural MRI functional reactivity to an episodic memory task, and undergo a comprehensive neurocognitive battery.

Drug: 18F-PI-2620 PET/CT

Interventions

18F-PI-2620 PET/CT DRUG

PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.

Also known as: PI-2620

Tau PET/CT

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• OUD OD- group:
• years-old
• Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
• Participants meet for lifetime OUD and are currently in medication-assisted treatment for OUD, which must include being on a stable dose of medication for at least 30 days prior to the screening visit.
• No lifetime history of OD per self-report, Drug Overdose Questionnaire, and/or medical record review.
• OUD OD+ group:
• years-old
• Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
• Participants meet for lifetime OUD and are currently in medication-assisted treatment for OUD, which must include being on a stable dose of medication for at least 30 days prior to the screening visit.
• A history of at least 1 opioid OD that required naloxone reversal that occurred up to 5 years prior to study enrollment, as per self-report, Drug Overdose Questionnaire, and/or medical record review.
• Healthy Control (HC) group:
• years-old
• Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
• Must have never met lifetime history for Alcohol Use Disorder, Substance Use Disorder --other than cannabis, tobacco or nicotine use disorder (as per DSM-5) and not used an opioid for any reason in the 30 days prior to screening by self-report, medical record review, and urine drug testing at screening.
• Must provide a negative urine drug screen on the day of the screening, MRI and PET scan visits for all substances (other than cannabis).

You may not qualify if:

• HIV infection confirmed by an on-site rapid HIV test at screening. HIV affect neurocognitive function, even in otherwise asymptomatic individuals, which can confound the results of MRI testing.
• The urine drug screening \& pregnancy test (for women of child-bearing potential) at the screening visit, MRI visit, and PET/CT scan visits must be negative for pregnancy (all groups) or will be deemed ineligible to participate. Participants in the healthy control group with a positive drug screen will be ineligible.
• At screening, the participant's weight is \>350 lb.
• Self-reported claustrophobia, which in the opinion of an investigator would interfere with acquisition of the structural MRI required for PET co-registration, and/or the PET scan itself.
• Contraindications to MRI (e.g., metal in the body that cannot be removed and is not MRI compatible). An MRI screening form will be completed during screening to identify contraindications.
• Screening lab values that indicate significant organ dysfunction that in the opinion of an investigator could compromise participant safety or successful participation in the study.
• History of epilepsy or seizure disorder (that are not a result of substance use or substance withdrawal in OUD+ groups) as assessed by medical record review or self-report.
• History of head trauma that in the opinion of an investigator may interfere with the uptake of applicable radiotracer as assessed by medical record review or self-report.
• Current serious psychiatric disorder (bipolar disorder, schizophrenia, psychotic disorder, eating disorder, or major depressive disorder with suicidal ideation or psychotic features) identified by medical record review, clinical examination or structured psychiatric interview that could interfere with study participation or make it hazardous for the participant or staff to perform study procedures.
• Self-reported heavy daily use of psychoactive substances in the past 30 days (prior to the screening visit), such as stimulants, cocaine, but not including nicotine, caffeine, cannabis (or opioids in the OUD groups) that could interfere with study performance.
• Not able to provide a breath alcohol level of 0.000 (tested with handheld breath analyzer) at the screening, MRI and/or PET scan visits.
• Inability to tolerate imaging procedures as determined by an investigator or treating physician
• Any current medical condition, illness, or disorder assessed by medical record review and/or self-report that is considered by a physician or investigator to potentially compromise participant safety or their successful participation in the study

Sponsors & Collaborators

• University of Pennsylvania: lead
• Yale University: collaborator

Study Sites (1)

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Opioid-Related Disorders; Pick Disease of the Brain

Interventions

PI-2620

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Frontotemporal Dementia; Frontotemporal Lobar Degeneration; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders

Study Officials

• Ilya Nasrallah, MD, PhD

  Univeristy of Pennsylvania

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: The analyses for the three aims will use analysis of variance to test for group differences among the three groups (OUD/OD+, OUD/OD-, HC).

Study Record Dates

• First Submitted: December 1, 2022
• First Posted: December 15, 2022
• Study Start: September 21, 2023
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: January 20, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)